Vadadustat
- Generic Name
- Vadadustat
- Brand Names
- Vafseo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H11ClN2O4
- CAS Number
- 1000025-07-9
- Unique Ingredient Identifier
- I60W9520VV
- Background
One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in erythropoietin (EPO) production. The treatment of anemia associated with chronic kidney disease (CKD) has traditionally involved the administration of exogenous erythropoiesis-st...
- Indication
Vadadustat is indicated for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
- Associated Conditions
- Symptomatic Anemia
- Associated Therapies
- -
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 134
- Registration Number
- NCT03801733
- Locations
- 🇨🇦
InVentiv Health Clinique Inc., Québec City, Quebec, Canada
Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT03801759
- Locations
- 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
- Conditions
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 175
- Registration Number
- NCT03799627
- Locations
- 🇺🇸
Research Site, Wauwatosa, Wisconsin, United States
🇺🇸Research Site #2, Minneapolis, Minnesota, United States
🇺🇸Research Site #1, Minneapolis, Minnesota, United States
A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03799848
- Locations
- 🇺🇸
American Research Corporation at the University of Texas Liver Institute, San Antonio, Texas, United States
🇺🇸Prism Clinical Research, Saint Paul, Minnesota, United States
Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat
- Conditions
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03789032
- Locations
- 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada
A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT03657290
- Locations
- 🇺🇸
Paraxel International, Baltimore, Maryland, United States
Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Akebia Therapeutics
- Registration Number
- NCT03242967
- Locations
- 🇺🇸
Research Site, Northridge, California, United States
Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT03140722
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States
Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 51
- Registration Number
- NCT03054337
Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT03054350
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.